DexCom, Inc.

AED315.57AED0.00 (+0.00%)
Last updated on --.

DexCom, Inc. price

24 Hours+0.00%AED0.00
30 days+1.46%+AED4.554
60 days-4.27%-AED14.07
90 days+18.14%+AED48.44

About DexCom, Inc.

DexCom, Inc. is a medical technology company primarily focused on innovating, developing, and marketing continuous glucose monitoring (CGM) systems. Operating across the United States and internationally, the firm provides its solutions for individuals managing diabetes as well as for healthcare practitioners. Its product portfolio features the DexCom G6, a comprehensive CGM system for diabetes management; the Dexcom Real-Time API, enabling authorized third-party developers to integrate live CGM data into their digital health applications; the Dexcom ONE, which aims to supersede traditional finger-prick blood glucose testing for treatment decisions; and Dexcom Share, a remote monitoring platform. The company is also developing the Dexcom G7, its next-generation CGM system. Furthermore, DexCom, Inc. has a licensing and collaboration agreement with Verily Life Sciences LLC and Verily Ireland Limited to advance blood-based or interstitial glucose monitoring products. The company directly sells its offerings to specialists such as endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and maintains its headquarters in San Diego, California.

Stock ticker
DXCM
Company
DexCom, Inc.
Industry
Healthcare
Category
US
Stock split / reverse split
14
Launch date
Apr 14, 2005
Listed exchange
NASDAQ

Financials

Q2 FY2026 Earnings
Report period: Apr 1, 2026 – Jun 30, 2026

Summary: DXCM reported Revenue of 1.31B (+13.08%), beating expectations; EPS of 0.70 (+45.83%), beating expectations.

Revenue (USD)Beat1.31B+13.07%1.29B+14.73%18.08M+1.40%
EPS (USD)Beat0.70+45.83%0.61+37.73%0.09+14.56%
Financial estimates
● Actual● Estimate
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
0.450.700.680.510.64
+28.57%+105.88%+78.94%+88.88%+42.22%
● EPS● YoY
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
7.33B7.50B6.34B6.63B6.46B
4.75B4.77B3.59B3.68B3.83B
64.88%63.65%56.68%55.42%59.39%
● Assets● Liabilities● Ratio
Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
303.00M659.90M294.00M525.60M269.20M
+8.44%+230.77%-2.46%+185.96%-11.16%
● CFO● YoY

Shareholders

Shareholders
BLACKROCK, INC.9.96%
VANGUARD CAPITAL MANAGEMENT LLC6.57%
VANGUARD PORTFOLIO MANAGEMENT LLC5.12%
STATE STREET CORP4.77%
INVESCO LTD.3.98%
Others69.58%
Institutions
% Owned101.12%+5.99%
Shares held389.42M+23.07M
Institutions1,024+13
% OwnedPrice
Name% OwnedChange
BLACKROCK, INC.9.96%-720.23K
VANGUARD CAPITAL MANAGEMENT LLC6.57%+188.79K
VANGUARD PORTFOLIO MANAGEMENT LLC5.12%+436.59K
STATE STREET CORP4.77%+445.96K
INVESCO LTD.3.98%+7.21M

Dividends

Stock splits
Launch date: Apr 14, 2005
DateRatio
Jun 13, 20221 → 4

DexCom, Inc. conversion tables

DXCMDXCM
AEDAED
0.5 DXCM157.78 AED
1 DXCM315.56 AED
5 DXCM1,577.83 AED
10 DXCM3,155.66 AED
AEDAED
DXCMDXCM
0.5 AED0.0015844 DXCM
1 AED0.0031689 DXCM
5 AED0.015844 DXCM
10 AED0.031689 DXCM

More to explore

FAQ

DXCM is trading at AED315.57, +0.00% over the last 24 hours. Track live moves on the price chart at the top of this page.

The DXCM stock forecast depends on a mix of factors — broader market conditions, sector trends, and company-specific drivers like earnings, product cycles, and macro signals. DXCM is currently trading at AED315.57, +0.00% over the last 24 hours, which reflects how the market is pricing these factors today. For a longer-term outlook on DXCM price action, review the 30-day, 60-day, and 90-day performance shown above, monitor momentum across the Healthcare sector, and watch overall market sentiment. Stock forecasts and price predictions are inherently uncertain — always DYOR.

P/E ratio (Price-to-Earnings, trailing twelve months) measures how much investors pay per dollar of earnings over the last 12 months. DXCM's P/E ratio is currently 33.82 — calculated by dividing its share price by its trailing 12-month earnings per share (EPS). A higher P/E suggests investors expect stronger future growth from DXCM; a lower P/E may indicate the stock is undervalued or that the market is pricing in a weaker outlook. P/E ratios are most useful when compared against DXCM's historical range and other companies in the Healthcare sector.

DexCom, Inc.'s market cap is currently 118.58B AED. Market cap is calculated as stock price × total shares outstanding.

Disclaimer

The social content on this page ("Content"), including but not limited to tweets and statistics provided by LunarCrush, is sourced from third parties and provided "as is" for informational purposes only. OKX does not guarantee the quality or accuracy of the Content, and the Content does not represent the views of OKX. It is not intended to provide (i) investment advice or recommendation; (ii) an offer or solicitation to buy, sell or hold digital assets; or (iii) financial, accounting, legal or tax advice. Digital assets, including stablecoins and NFTs, involve a high degree of risk and can fluctuate greatly. The price and performance of the digital assets are not guaranteed and may change without notice.

OKX does not provide investment or asset recommendations. You should carefully consider whether trading or holding digital assets is suitable for you in light of your financial condition. Please consult your legal/tax/investment professional for questions about your specific circumstances. For further details, please refer to our Terms of Use and Risk Warning.